About The Study: Among people with chronic obstructive pulmonary disease (COPD) at high risk of exacerbation, treatment with the β1-selective β-blocker bisoprolol did not reduce the number of self-reported COPD exacerbations requiring treatment with oral corticosteroids, antibiotics, or both.
About The Study: Among people with chronic obstructive pulmonary disease (COPD) at high risk of exacerbation, treatment with the β1-selective β-blocker bisoprolol did not reduce the number of self-reported COPD exacerbations requiring treatment with oral corticosteroids, antibiotics, or both.
Quote from corresponding author Graham Devereux, M.D.:
“People with COPD are at increased risk of cardiovascular conditions that benefit from treatment with beta-blockers. However, there is a well-documented reluctance for physicians to prescribe beta-blockers for people with cardiovascular disease and COPD.
“These findings will help physicians and patients with COPD assess the risks and benefits of using bisoprolol to treat cardiovascular disease.”
Contact information for Graham Devereux, M.D.: email graham.devereux@lstmed.ac.uk.
To access the embargoed study: Visit our For The Media website at this link
(doi:10.1001/jama.2024.8771)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Media advisory: This study is being presented at the American Thoracic Society 2024 International Conference.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time
Journal
JAMA
